Multifocal HCC · LI-RADS + TRA v2024 — Milan/UNOS Transplant Criteria
Structured reporting for diagnosis, treatment response assessment, and transplant eligibility in hepatocellular carcinoma. Milan, UNOS T2, downstaging, UCSF, and Up-to-7 evaluated automatically.
LI-RADS applies only to patients at high risk for HCC.
ECOG 0 fully active · 1 mild limitation · ≥2 may influence treatment candidacy
Auto-calculates Child-Pugh, MELD-Na, and AFP category.
Clinically significant portal hypertension absent.
Add unlimited lesions. LI-RADS category auto-derives from major features.
Ancillary features favoring HCC
Ancillary favoring benignity
LR-M features (targetoid / infiltrative)
All vessels patentEditCollapse
Single ≤5 cm OR up to 3 lesions each ≤3 cm; no macrovascular invasion or extrahepatic disease.
- • Beyond Milan criteria.
Aligned with Milan; AFP ≤1000 ng/mL required for listing.
- • Tumor burden (n=0, largest 0.0 cm, sum 0.0 cm) exceeds UNOS downstaging criteria.
1 lesion 5–8 cm · 2–3 lesions each ≤5 cm (sum ≤8 cm) · 4–5 lesions each ≤3 cm (sum ≤8 cm).
- • UCSF: Not met.
- • Up-to-7: Met (score 0.0).
Extended reference criteria.
Auto-derived from lesion burden, vascular, hepatic reserve, and prior therapy data above.
Ablation eligibilityInsufficient data
Complete lesion size and burden data to assess.
- • Largest lesion — (ideal ≤3 cm; up to 4 cm acceptable).
- • 0 lesions (favor ≤3 lesions).
- • Macrovascular invasion: absent.
- • Extrahepatic disease: absent.
TACE eligibilityInsufficient data
Complete lesion, vascular, and Child-Pugh data to assess.
- • Macrovascular invasion: absent.
- • Extrahepatic disease: absent.
- • Bilirubin 0.0 mg/dL (caution if >2, avoid if >3).
- • Tumor burden: 0 lesions, largest —.
Y90 radioembolization suitabilityInsufficient data
Complete vascular, hepatic reserve, and burden data to assess.
- • Macrovascular invasion: absent.
- • Extrahepatic disease: absent.
- • Bilirubin 0.0 mg/dL (avoid Y90 if >2 without segmental targeting).
- • Tumor burden: 0 lesions, largest —.
Systemic therapy considerationsInsufficient data
Complete stage, hepatic reserve, and performance data to assess.
- • Macrovascular invasion: absent.
- • Extrahepatic disease: absent.
- • Ablation: Insufficient data
- • TACE: Insufficient data
- • Y90: Insufficient data
- • Systemic therapy: Insufficient data
Solitary hepatic observation with tumor burden beyond Milan and downstaging criteria, without macrovascular invasion or extrahepatic disease.
• Macrovascular invasion absent; extrahepatic disease absent. • No measurable hepatic observations characterized. • MELD-Na 22.
- Complete lesion characterization to generate recommendations.